RT Journal Article
T1 Use of multikinase inhibitors/lenvatinib concomitant with locoregional therapies for the treatment of radioiodine-refractory differentiated thyroid cancer.
A1 Berciano-Guerrero, Miguel-Ángel
K1 enolization
K1 lenvatinib
K1 radiotherapy
K1 surgery
AB Locoregional recurrence of differentiated thyroid cancer (DTC) occurs in 20% of thyroid cancer patients. Currently, there are many strategies for management of locoregional recurrence of DTC that lead to local control of the disease. The introduction of lenvatinib into the therapeutic armamentarium provides a new option for the treatment of radioiodine-refractory DTC (RR-DTC). However, results for simultaneous treatment with lenvatinib and locoregional therapies are unknown in patients with RR-DTC. This paper reviews the current status of this approach and gives recommendations on the management of lenvatinib during concomitant locoregional procedures.
YR 2022
FD 2022
LK http://hdl.handle.net/10668/21285
UL http://hdl.handle.net/10668/21285
LA en
DS RISalud
RD Apr 8, 2025